Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

FIRE-8 is a prospective, randomized, open label, multicenter phase II clinical trial. To evaluate the effecacy of trifluridine / tipiracil and panitumumab (Arm A) compared to trifluridine / tipiracil and bevacizumab (Arm B), participants will be randomly assigned to either Arm A or Arm B for the treatment of metastatic colorectal cancer. The primary objectives of this study is to compare the effecacy of treatment with trifluridine / tipiracil plus panitumumab versus trifluridine / tipiracil plus bevacizumab.

Trial Details

NCT ID
NCT05007132
Phase
PHASE2
Sponsor
Dominik Paul Modest
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Panitumumab 20 milligram/ML
  • Bevacizumab
  • Trifluridine/Tipiracil Hydrochloride
Locations (sample)
  • Berlin, Germany|52.52437,13.41053

Key Eligibility Criteria

  • Patient's signed informed consent
  • Patients ≥ 18 years at the time of signing the informed consent
  • Histologically confirmed adenocarcinoma of the colon or rectum
  • Metastatic colorectal cancer (mCRC) with at least one measurable lesion according to RECIST 1.1 in a computed tomography (CT) or magnetic resonance…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →